Latest Shareholder Approvals News

TPG Telecom reported solid half-year results with 2.2% revenue growth driven by mobile subscribers and a 35% surge in operating free cash flow. The company announced a $3 billion capital reduction and a maintained dividend policy, signaling confidence despite ongoing network expansion costs.

Perseus Mining Limited has announced an on-market buy-back program to repurchase up to 40 million ordinary shares over the next year, signaling a strategic move in capital management.

Wesfarmers has announced a $1.50 per share capital management initiative, combining a $1.10 return of capital with a $0.40 fully-franked special dividend, pending shareholder approval at the upcoming AGM.

Wesfarmers delivered a solid FY25 with revenue rising 3.4% to $45.7 billion and net profit after tax up 14.4%, driven by strong performances in Bunnings and Kmart. The company announced increased dividends and a proposed capital return, while navigating challenges in its lithium business and ongoing cost pressures.

Wesfarmers Limited reported a 14.4% rise in net profit for FY2025, driven by strong retail performances and strategic portfolio moves. The company also announced a fully-franked final dividend and a significant capital management distribution, signaling confidence amid economic headwinds.

Wesfarmers Limited reported a robust 2025 financial year with a 14.4% increase in net profit after tax to $2.926 billion and declared fully franked dividends of $2.06 per share. The conglomerate also unveiled a proposed $1.50 per share capital management distribution, pending shareholder approval.

Platinum Asset Management reports improved FY2025 financials alongside a transformative merger proposal with L1 Capital, aiming to create a $16.5 billion alternative asset manager.

Platinum Asset Management reported a sharp 86% drop in profit for FY25, driven by a 39% decline in funds under management amid sustained outflows and investment challenges. The company announced a transformative merger with L1 Capital, aiming to create a $16.5 billion asset manager.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Savannah Goldfields Limited has announced a $15 million equity raising through a placement and conditional placement, offering free attaching options subject to shareholder approval. The capital raise aims to strengthen the company’s financial position and support its operational restart plans.

H&G High Conviction Limited reported a $2.9 million net loss for FY2025 amid challenging market conditions and completed a major asset sale to Hancock & Gore Limited, marking a pivotal shift in its business model.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.